R&D
JP Morgan 2024 – Graham Heap

JP Morgan 2024 – Graham Heap

Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D